Supernus Pharmaceuticals
SUPN
246 hedge funds and large institutions have $1.67B invested in Supernus Pharmaceuticals in 2023 Q4 according to their latest regulatory filings, with 32 funds opening new positions, 85 increasing their positions, 89 reducing their positions, and 21 closing their positions.
52% more first-time investments, than exits
New positions opened: 32 | Existing positions closed: 21
7% more capital invested
Capital invested by funds: $1.57B → $1.67B (+$104M)
3% more funds holding
Funds holding: 238 → 246 (+8)
1.55% more ownership
Funds ownership: 104.37% → 105.91% (+1.5%)
2% less call options, than puts
Call options by funds: $766K | Put options by funds: $778K
4% less repeat investments, than reductions
Existing positions increased: 85 | Existing positions reduced: 89
33% less funds holding in top 10
Funds holding in top 10: 3 → 2 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
+$24.3M |
| 2 |
Schroder Investment Management Group
London,
United Kingdom
|
+$14.4M |
| 3 |
PCH
Polar Capital Holdings
London,
United Kingdom
|
+$7.55M |
| 4 |
BlackRock
New York
|
+$5.38M |
| 5 |
SIMG
Stephens Investment Management Group
Houston,
Texas
|
+$5.31M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BG
Bellevue Group
Kuesnacht,
Switzerland
|
-$15M |
| 2 |
AC
Armistice Capital
New York
|
-$11.7M |
| 3 |
IHAM
Integral Health Asset Management
New York
|
-$6.07M |
| 4 |
FCM
Frontier Capital Management
Boston,
Massachusetts
|
-$5.53M |
| 5 |
Citadel Advisors
Miami,
Florida
|
-$4.39M |
SUPN Hedge Fund Activity: Q4 2023 in Review
246 of the 6,859 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q4 2023, worth a combined $1.67B — up 6.6% from $1.57B a quarter earlier.
Buyers outnumbered sellers: 32 funds opened new SUPN positions and 21 closed out — a net gain of 11 holders — while 85 added to existing stakes and 89 trimmed.
The largest buyer was Morgan Stanley, adding an estimated $24.3M. The largest seller was Bellevue Group, cutting an estimated $15M.
- 246 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q4 2023, up from 238 in Q3 2023.
- Funds reported $1.67B of Supernus Pharmaceuticals stock for Q4 2023, up 6.6% quarter-over-quarter.
- 32 funds opened new Supernus Pharmaceuticals positions in Q4 2023 and 21 closed out, a net change of +11 holders.
- The largest Supernus Pharmaceuticals buyer in Q4 2023 was Morgan Stanley, an estimated $24.3M added.
- The largest Supernus Pharmaceuticals seller in Q4 2023 was Bellevue Group, an estimated $15M sold.
Based on aggregated 13F filings for Q4 2023.